黄芪下瘀血汤加味治疗气虚血瘀型代谢相关脂肪性肝病患者的临床研究OA
Retrospective clinical study of modified Huangqi Xiayuxue decoction in the treatment of metabolic dysfunction-associated fatty liver disease with Qi-deficiency and blood-stasis syndrome
目的:综合评价黄芪下瘀血汤加味治疗气虚血瘀型代谢相关脂肪性肝病(MAFLD)及其对代谢综合征(MetS)的临床疗效.方法:回顾性分析127例气虚血瘀型MAFLD患者的临床资料,根据实际治疗方案分为治疗组(n=65)与对照组(n=62).对照组患者接受健康宣教及常规西医保肝治疗,治疗组患者在对照组治疗基础上加用黄芪下瘀血汤加味,两组患者疗程均超过24周.比较两组患者治疗前后的肝功能[丙氨酸氨基转移酶(ALT)、天门冬氨酸氨基转移酶(AST)、γ-谷氨酰转移酶(GGT)]、血脂[甘油三酯(TG)、总胆固醇(TC)、低密度脂蛋白胆固醇(LDL-C)]、肝脏B超、受控衰减参数(CAP)、肝硬度测量值(LSM)、纤维化-4指数(FIB-4)、体质量指数(BMI)、MetS组分及中医证候积分.结果:治疗后,治疗组在改善肝功能(ALT、AST、GGT)、血脂(TG、TC、LDL-C)、BMI、CAP和LSM均显著优于对照组(均P<0.05).治疗组基于肝脏B超和CAP评估的总有效率分别为64.6%和67.7%,均显著高于对照组的37.1%和40.3%(均P<0.05).在MetS方面,治疗组MetS组分数量、空腹血糖(FBG)及收缩压(SBP)的改善亦显著优于对照组(P<0.05).疾病谱分析显示,治疗组中55.0%显著纤维化患者实现LSM逆转,显著高于对照组的15.8%(P<0.05).中医证候疗效总有效率治疗组(86.2%)显著高于对照组(19.4%)(P<0.01).治疗期间两组均未发生不良反应.结论:黄芪下瘀血汤加味能显著改善气虚血瘀型MAFLD患者的肝功能、血脂、肝脏脂肪沉积及纤维化程度,有效降低BMI,调节全身代谢状态,并显著缓解中医临床症状,且安全性良好.
Objective:To comprehensively evaluate the clinical efficacy of modified Huangqi xiayuxue Decoction(HD)in treating Metabolic dysfunction-associated fatty liver disease(MAFLD)with qi-deficiency and blood-stasis syndrome and its impact on Metabolic Syndrome(MetS).Methods:A retrospective study was conducted involving 127 MAFLD patients with qi-deficiency and blood-stasis syndrome.According to the actual treatment regimen,patients were assigned to a treatment group(n=65)and a control group(n=62).The control group received health education and conventional Western liver-protecting therapy,while the treatment group received additional HD based on the control group's treatment.The treatment course exceeded 24 weeks for both groups.Changes in liver function[alanine aminotransferase(ALT),aspartate aminotransferase(AST),gamma-glutamyl transferase(GGT)],blood lipids[triglycerides(TG),total cholesterol(TCh),low-density lipoprotein cholesterol(LDL-C)],liver ultrasound B,controlled attenuation parameter(CAP),liver stiffness measurement(LSM),fibrosis-4 index(FIB-4),body mass index(BMI),MetS components,and traditional Chinese medicine(TCM)syndrome scores were compared before and after treatment.Results:After treatment,the improvement in liver function(ALT,AST,GGT),blood lipids(TG,TCh,LDL-C),BMI,CAP,and LSM in the treatment group was significantly superior to that in the control group(all P<0.05).The total effective rates for improvement based on liver ultrasound B and CAP in the treatment group were 64.6%and 67.7%,respectively,both significantly higher than those in the control group(37.1%and 40.3%)(both P<0.05).Regarding MetS,the improvement in the number of metabolic abnormality components,fasting blood glucose,and systolic blood pressure in the treatment group was also significantly better than that in the control group(P<0.05).Disease spectrum analysis showed that 55.0%of patients with significant fibrosis at baseline in the treatment group achieved LSM reversal,which was significantly higher than the 15.8%in the control group(P=0.011).The total effective rate for TCM syndrome efficacy in the treatment group(86.2%)was significantly higher than that in the control group(19.4%)(P<0.001).No adverse events were reported in either group during the treatment period.Conclusion:HD can significantly improve liver function,blood lipids,hepatic fat deposition,and fibrosis degree,effectively reduce BMI,regulate systemic metabolic status,and significantly alleviate TCM clinical symptoms in MAFLD patients with qi-deficiency and blood-stasis syndrome,demonstrating good safety.
尹晓薇;李旭涛;金晋;谭英斌;成扬
昆山市中西医结合医院脾胃科(江苏 昆山,215332)||上海中医药大学附属曙光医院肝病研究所上海中医药大学附属曙光医院肝病研究所上海中医药大学附属曙光医院肝病研究所昆山市中西医结合医院脾胃科(江苏 昆山,215332)上海中医药大学附属曙光医院肝病研究所
医药卫生
代谢相关脂肪性肝病气虚血瘀型黄芪下瘀血汤代谢综合征
metabolic dysfunction-associated fatty liver diseaseQi-deficiency and blood-stasis syndromeHuangqi Xiayuxue decoctionmetabolic syndrome
《中西医结合肝病杂志》 2026 (8)
957-961,5
江苏省昆山市社会发展科技专项(No.KSZ2253),国家自然基金面上项目(No.81774098)
评论